The global drug eluting stents (DES) market size is forecast to reach USD 8.98 billion by 2026, substantially to the increasing prevalence of cardiovascular diseases worldwide. A drug eluting stent is a semi-rigid device in the form of a tube that is coated with They help to reduce restenosis cases and also limits the risk of late or early thrombosis in patients.

More information on the market is provided in a recently published report by Fortune Business Insights ™ titled, “Drug Eluting Stents (DES) Market Size, Share & Industry Analysis, By Type (Coronary Stenting, and Peripheral Stenting), By Product (Polymer- based, and Polymer-free), By Scaffold (Cobalt-Chromium, Platinum-Chromium, Nitinol and Others), By Drug (Sirolimus, Paclitaxel, Zotarolimus, Everolimus, and Others), By End User (Hospitals, and Specialty Clinics), and Regional Forecast, 2019-2026. ”As per this report, the market value was USD 5.71 billion in 2019 and will exhibit a CAGR of 6.7% between 2019 to 2026.

visit: 

Improving Healthcare Infrastructure in developing nations will Propel Growth

The increasing cases of cardiovascular diseases worldwide are a significant factor in boosting the global market for drug eluting stents. Besides this, government-supported reimbursement policies and a rise in expenditure on research and development of better stents are also aiding in the expansion of the market This, coupled with the FDA approvals and CE marks received by many stents, is expected to promote the drug eluting stents market growth in the forecast period.

Rising Incidences of Cardiovascular Diseases will Help Asia Pacific witness Significant Growth

Currently, North America is holding the dominant drug eluting stents market share owing to the increasing prevalence of cardiovascular diseases and the supported reimbursement policies supported by governments in the region. In 2018, this region generated a revenue of USD 1.80 billion. Additionally, the increasing trend of biodegradable polymer-based drug eluting scaffolds may further help this region continue dominance in the forecast period as well. On the other side, the market in Europe will emerge as the fastest-growing region owing to the rise in the number of third- generation DES with the CE mark and the rising popularity of polymer technology for the production of stents.the increasing cases of cardiovascular diseases and the improving medical infrastructure and medical facilities will help Asia Pacific witness significant growth in the coming years.